We have located links that may give you full text access.
JOURNAL ARTICLE
META-ANALYSIS
REVIEW
An overview on the methodological and reporting quality of dose-response meta-analysis on cancer prevention.
BACKGROUND: Dose-response meta-analysis (DRMA) has been widely used in exploring cancer risk factors. Understanding the quality of published DRMAs on cancer risk factors may be beneficial for informed prevention for cancer.
METHODS: We searched eligible DRMAs from 1st January 2011 to 31st-July-2017. The modified AMSTAR 1.0 (15 items) and PRISMA checklist (26 items) were used to evaluate the methodological and reporting quality of included DRMAs. We compared the adherence rate of these items by journal type, publication years, region, and funding information, in prior.
RESULTS: We included 260 DRMAs. Colorectal, breast, prostate, and lung were the four most commonly investigated cancers. For methodological quality, 6 out of 15 items were adhered by less than 30% of the DRMAs, 2 by less than 60%, only 7 of which by 80% or more. For reporting quality, 3 out of 26 items were adhered by less than 30% of the DRMAs, 1 by less than 80% (> 30%), and 20 of which by 80% or more. Those published in general journal, published more recently, and received any financial support have better methodological (Rate differences, RDs = 10-36%; P < 0.05) and reporting adherence (RDs = 12-36%; P < 0.05). DRMAs by Asian author tend to be less qualified than by European and American.
CONCLUSIONS: The methodological quality of DRMAs on cancer risk factors is worrisome that the findings of them may be deflective; more efforts are needed to improve the validity of it.
METHODS: We searched eligible DRMAs from 1st January 2011 to 31st-July-2017. The modified AMSTAR 1.0 (15 items) and PRISMA checklist (26 items) were used to evaluate the methodological and reporting quality of included DRMAs. We compared the adherence rate of these items by journal type, publication years, region, and funding information, in prior.
RESULTS: We included 260 DRMAs. Colorectal, breast, prostate, and lung were the four most commonly investigated cancers. For methodological quality, 6 out of 15 items were adhered by less than 30% of the DRMAs, 2 by less than 60%, only 7 of which by 80% or more. For reporting quality, 3 out of 26 items were adhered by less than 30% of the DRMAs, 1 by less than 80% (> 30%), and 20 of which by 80% or more. Those published in general journal, published more recently, and received any financial support have better methodological (Rate differences, RDs = 10-36%; P < 0.05) and reporting adherence (RDs = 12-36%; P < 0.05). DRMAs by Asian author tend to be less qualified than by European and American.
CONCLUSIONS: The methodological quality of DRMAs on cancer risk factors is worrisome that the findings of them may be deflective; more efforts are needed to improve the validity of it.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app